A randomised controlled trial to assess the role of resistance assays in Human Immunodeficiency Virus (HIV) infectio

HS R&D Regional Programme Register - Department of Health (UK)0 个研究点目标入组 480 人开始时间: 2004年1月23日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Confirmed HIV-positive
•2. Age 18 years or more
•3. Expected to live at least 12 months
•4. Able to give informed consent
•5. Currently receiving antiretroviral therapy
•6. Most recent HIV ribonucleic acid (RNA) >2000 copies/ml
•7. Clinician and patients have decided to change therapy on the basis of virological failure
•8. Clinician considers that a resistance test may influence selection of new drug regimen, and clinician and patient are prepared to wait for the result (up to 1 month) before changing treatment

•1. Naive to antiretroviral drugs or previous exposure to 1 or 2 nucleoside analogue reverse transcriptase inhibitors only
•2. Part A only: a resistance test (genotypic or phenotypic) had previously been performed or patient would have had a local resistance test
•3. Part B only: a phenotypic resistance test had previously been performed
•4. Participation in certain trials of antiretroviral therapies, considered on a case-by-case basis
•5. Was unlikely to comply with routine schedule of visits

发起方

HS R&D Regional Programme Register - Department of Health (UK)